Are there health risks associated with long-term use of mitapivat-Pyrukynd?

Mitapivat-Pyrukynd, as a new pyruvate kinase (PK) activator, has shown good efficacy in the treatment of hemolytic anemia caused by PK deficiency. However, whether there are health risks to patients taking long-term mitava remains a matter of concern.

According to the available clinical data, metapival is relatively safe when used in the short term and is generally tolerated by patients. However, the safety of long-term use still requires further research and observation. Here are some potential long-term health risks:

1. Liver and kidney function problems: Since Metapival is metabolized by the liver, long-term use may have a certain impact on liver function. Although existing studies have not shown significant liver toxicity, long-term use may still require regular monitoring of liver function indicators. In addition, renal clearance of the drug may also be affected, especially in patients with other medical conditions, requiring special caution.

2. Metabolic abnormalities: One of the side effects of mitapival is that it may lead to an increase in uric acid levels. Therefore, patients may be at risk of hyperuricemia during long-term use. Elevated uric acid can lead to problems such as gout or kidney stones. Therefore, it is very important for patients on long-term use of mitava to regularly check uric acid levels and take necessary management measures.

3. Abnormal hormone levels: Long-term use of Metapival may lead to a decrease in estrone and estradiol levels in male patients. Although these changes are usually reversible, long-term changes in hormone levels may still have a certain impact on men's health. Hormone levels need to be monitored regularly and hormone replacement therapy taken if necessary.

4. Skeletal and muscle problems: Mitapival may also cause musculoskeletal discomforts such as joint pain and back pain. These symptoms may be aggravated with long-term use and affect the patient's quality of life. Therefore, patients should pay attention to relieving these uncomfortable symptoms and take appropriate treatment measures during long-term use.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/pyrukynd